Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: mode of action (Q44235401)

1 December 2017

title

Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: mode of action (English)

1 reference

1 December 2017

3

Issei Komuro

1 reference

1 December 2017

2

Takehiko Ogura

1 reference

1 December 2017

Shunichi Kushida

1

1 reference

1 December 2017

Haruaki Nakaya

series ordinal

4

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

European Journal of Pharmacology

1 December 2017

published in

1 reference

1 December 2017

volume

457

1 reference

1 December 2017

issue

1

1 reference

1 December 2017

page(s)

19-27

1 reference

MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

Use-dependent block and use-dependent unblock of the delayed rectifier K+ current by almokalant in rabbit ventricular myocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

Antiarrhythmic agent, MS-551, protects against pinacidil + hypoxia-induced ventricular fibrillation in Langendorff-perfused rabbit isolated heart.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

MS-551 protects against ventricular fibrillation in a chronic canine model of sudden cardiac death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

Effects of the new class III antiarrhythmic drug MS-551 and d-sotalol on canine coronary ligation-reperfusion ventricular arrhythmias.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

Efficacy of nifekalant hydrochloride on the treatment of life-threatening ventricular tachyarrhythmias during reperfusion for acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

Effects of MS-551, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

Inhibition of ATP-sensitive potassium channels in cardiac myocytes by the novel class III antiarrhythmic agent MS-551

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

A structural basis for drug-induced long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells. Different molecular mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

Effects of MS‐551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

The inward rectification mechanism of the HERG cardiac potassium channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

HERG, a Human Inward Rectifier in the Voltage-Gated Potassium Channel Family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

Survival with oral d-Sotalol in patients with left ventricular dysfunction after myocardial infarction: Rationale, design, and methods (the SWORD trial)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

Kinetics of rate-dependent shortening of action potential duration in guinea-pig ventricle; effects of IK1 and IKr blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902666-3

10.1016/S0014-2999(02)02666-3

7 January 2021

Identifiers

DOI

1 reference

1 December 2017

1 reference